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Natural killer (NK) cell alloreactivity correlates with improved
survival after T-cell deplete but not T-cell replete hematopoietic
cell transplantation (HCT), especially in myeloid diseases. Using
samples from the NMDP repository and clinical outcome data
from the CIBMTR we evaluated the effect of donor and recipient
KIR genotype on outcomes after URD HCT. Using a validated as-
say we genotyped donors and recipients from 836 HLA-matched and
915 mismatched T-replete URD transplantations performed be-
tween 1988 and 2003 for acute myelogenous leukemia (AML: n 5
456), acute lymphoblastic leukemia (ALL: n5 334), chronic myeloid
leukemia (CML: n5 765) or myelodysplastic syndrome (MDS: n5
196). Multivariate models evaluated the effect of donor and recipient
KIR genotypes (A/A: two A KIR haplotypes, or B/x: at least one B
haplotype; typically containing more activating KIR) on clinical out-
comes.
Transplantation from donors with KIR B haplotypes was associ-
ated with improved three year overall survival for patients with
AML (B/x: 31% [95% CI: 26–36] vs. A/A: 20% [95% CI: 14–27];
p\0.003). This survival benefit was confirmed using a multivariate
model which included disease status (early, intermediate, or ad-
vanced), HLA matching (10/10 or \10/10), performance status,
time to transplant, and age. The use of B/x donors compared to
A/A donors conferred a 26% improvement in the relative risk of
relapse-free survival (RR 0.74 [95% CI 0.59–0.93]; p 5 .01). This
improvement was partially explained by less relapse with use of
KIR B haplotype donors (RR 0.71 [95% CI 0.50–1.02]; p 5 .06).
However, KIR B haplotype donors were not associated with differ-
ences in OS, RFS or relapse in patients with ALL, CML, or MDS,
regardless of HLA matching or KIR-Ligand matching status. No
significant effects on TRM or GVHD were seen in any of the disease
cohorts. Analysis of this large cohort demonstrates that while
unrelated donors with KIR B haplotypes confer significant survival
benefit to patients receiving T-replete HCT for AML, the same
KIR haplotype effect is not evident in other diseases. This suggests
that AML blasts may be particularly sensitive to killing by NK cells
and raises the question as to whether activating genes present in the
KIR B haplotype may uniquely recognize ligands on AML blasts.
Further studies to understand and exploit those mechanisms are
warranted but present data can only support the choice of KIR B
haplotype donors in AML.
Effect of Donors with B KIR Haplotypes on Relapse-Free
Survival and Relapse after URD HCT
Donor KIR genotype
B/x (reference: A/A) Hazard ratio 95% CI p-valueRelapse-Free Survival
AML (n5456 0.74 (0.59, 0.93) 0.01
ALL (n5334) 0.92 (0.69, 1.22) 0.56
CML (n5765) 1.06 (0.86, 1.30) 0.61
MDS (n5196) 1.05 (0.72, 1.54) 0.80(Continued )(Continued )Donor KIR genotype
B/x (reference: A/A) Hazard ratio 95% CI p-valueRelapse
AML (n5456) 0.71 (0.50, 1.02) 0.06
ALL (n5334) 1.11 (0.70, 1.75) 0.66
CML (n5765) 0.80 (0.33, 1.94) 0.62
MDS (n5196) 0.95 (0.42, 2.13) 0.905
ALTERNATE DONOR HCT FOR FANCONI ANEMIA (FA): RESULTS OF
A TOTAL BODY IRRADIATION (TBI) DOSE DE-ESCALATION STUDY
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Great strides have been made in optimizing the conditioning reg-
imen for FA patients with their underlying defect in DNA repair.
Prior to 1995, survival rates after alternate donor hematopoietic
cell transplantation (AD-HCT) were poor (\20%). After 1999,
the addition of fludarabine (FLU) significantly improved engraft-
ment and survival. However, risks of infection and late effects re-
mained important challenges. Seeking to reduce these risks, we
conducted a single center, single arm, TBI dose de-escalation trial
designed to determine the lowest possible dose of TBI required for
engraftment after T cell depleted AD marrow (TCD BM). All pa-
tients received cyclophosphamide (CY) 10 mg/kg  4 days, FLU
35 mg/m2  4 days, ATG 30 mg/kg  5 days and a single fraction
of TBI with CT guided thymic shielding (TS). TBI dose de-escala-
tion strata were: TBI 300 cGy (cohort 1); TBI 150 cGy (cohort 2); no
TBI (cohort 3). All patients received CSA and methylprednisolone as
GVHD prophylaxis and G-CSF 5 ug/kg/day until engraftment. The
decision to proceed with each stepwise decrease in TBI was based
upon achieving primary neutrophil engraftment in 10 of 10 patients
at each dose level, or 14 of 15 patients if one graft failure occurred in
any of the first 10 patients. More than 1 graft failure in 15 patients
was considered unacceptable and the next higher TBI dose level
was then considered the optimal dose. Between July 2006-May
2008, 19 FA patients were enrolled with 17 in cohort 1 and 2 in co-
hort 2. Five patients received 5-6/6 unmanipulated UCB because
a BM donor could not be identified. All patients achieved primary
engraftment at a median of 11 days after AD-HCT. However, 2/2
patients who received TBI 150 developed secondary graft failure at
76 and 114 days after HCT. The dose de-escalation was stopped
with TBI 300 cGy identified as the lowest possible dose in the con-
text of FLU/CY given concomitantly. Thus far, 17 patients have
been treated with TBI 300. As shown, results compare favorably
with prior regimens using TBI 450 with and without TS (table)
Outcomes After AD-HCT in Standard Risk FA Patients
Neutrophil Acute Chronic 1 Year
N Engraftment GVHD GVHD SurvivalTBI 450 no TS 21 95% 24% 19% 67%
TBI 450 1 TS 12 92% 42% 8% 83%
TBI 300 1 TS 17 94% 25% 0% 92%TS 5 thymic shielding.
Our results demonstrate that TBI 300 cGy is sufficient for consis-
tent engraftment in recipients of CY-FLU-ATG and HLA matched
or mismatched TCD AD BM or UCB and represents a new standard3
4 CIBMTR Best Abstract Awards for Clinical Researchof care for this patient population. Longer follow up is needed to
quantitate the impact of lower dose radiation on immune recovery,
risks of infection, cancer risk and other therapy-related late effects.6
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In the era of allelic typing and with bone marrow transplantation
(BMT) in CR1 restricted to patients at higher risk of treatment fail-
ure, it is important to evaluate whether BMT using alternative family
donors is equivalent to using an HLA-matched sibling donor (MSD)
or an unrelated donor (URD). We compared the outcomes of pa-
tients \18y reported to CIBMTR from 1993–2006 with AML,
ALL, CML and MDS undergoing a first allogeneic BMT. Donors
were MSD (N 5 1208), URD (N 5 266) or a mismatched related
donor (mmRD), either a 1 antigen mismatch at HLA-A, B or
DRB1 (N5 97) or phenotypically matched related donor (N5 54).
mmRD were typed by serological or DNA-based methods with all
results verified by lab report review. URD were all 8/8 allelic matches
at HLA-A,B,C,DRB1 through the NMDP retrospective typingprogram. All patients received myeloablative conditioning, T-cell
replete bone marrow grafts and calcineurin inhibitor-based GVHD
prophylaxis. Recipients of URD had more intermediate/advanced
disease (p\0.01), were transplanted later after diagnosis (p\0.01)
and more received TBI (p\0.01). There were no significant differ-
ences (p\0.01) between the phenotypically matched and 1-Ag mis-
matched related donor groups, so they were combined in the final
multivariate model (as mmRD). Recipients of MSD had less acute
GVHD grades 3–4, chronic GVHD, 100-day mortality, TRM and
overall mortality (OM) as well as increased DFS compared with
both the URD and mmRD groups (Table). Relapse rates were
similar for all groups. Comparisons between the mmRD and URD
groups did not detect a difference in acute GVHD grades 3–4,
chronic GVHD, TRM, 100-day mortality, OM, DFS and relapse
(Table). In this large cohort of paediatric patients, MSD have supe-
rior outcomes to either mmRD or URD. An 8/8 allelic matched
URD results in outcome similar to mmRD. A family donor is an ac-
ceptable alternative to an allelic matched URD, but does not result in
the same outcome as a MSD.
Pairwise comparisons of mmRD vs. MSD and URD vs. mmRD
mmRD vs. MSD URD vs. mmRD
Outcome OR/RR* (95%CI), p OR/RR* (95%CI), p100-day mortality 2.54 (1.55-4.17),\0.01 0.95 (0.54-1.66), 0.85
Overall mortality 1.48 (1.12-1.97),\0.01 0.98 (0.72-1.33), 0.87
Disease-free survival 1.38 (1.09-1.75), 0.01 1.02 (0.77-1.35), 0.90
TRM 3.01 (2.10-4.33),\0.01 1.16 (0.77-1.64), 0.74
Relapse 0.90 (0.65-1.24), 0.52 1.09 (0.74-1.60), 0.66
Acute GVHD III-IV 3.41 (2.38-4.89),\0.01 0.75 (0.49-1.14), 0.18
Chronic GVHD 3.09 (2.24-4.27),\0.01 1.27 (0.88-1.82), 0.20*OR for 100-day mortality. RR for all other outcomes.
